Beskrovnaya Oxana 4
4 · Dyne Therapeutics, Inc. · Filed May 22, 2024
Insider Transaction Report
Form 4
Beskrovnaya Oxana
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-20$1.03/sh+30,426$31,339→ 180,073 total - Sale
Common Stock
2024-05-20$32.49/sh−17,134$556,684→ 162,939 total - Sale
Common Stock
2024-05-20$34.08/sh−1,145$39,022→ 149,647 total - Sale
Common Stock
2024-05-20$33.51/sh−12,147$407,046→ 150,792 total - Exercise/Conversion
Stock option (right to buy)
2024-05-20−30,426→ 0 totalExercise: $1.03Exp: 2030-01-05→ Common Stock (30,426 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.00 to $33.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.01 to $34.01, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.02 to $34.16, inclusive.
- [F5]Includes 130,308 unvested RSUs.
- [F6]The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter.